BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225-1233. [PMID: 23168362 DOI: 10.1016/s1470-2045(12)70509-0] [Cited by in Crossref: 364] [Cited by in F6Publishing: 407] [Article Influence: 36.4] [Reference Citation Analysis]
Number Citing Articles
1 Boutros CS, Hue JJ, Elshami M, Rothermel LD, Hoehn RS, Ammori JB, Winter JM, Ocuin LM, Hardacre JM. Management of adenocarcinoma of the pancreatic tail in the elderly. Journal of Surgical Oncology 2022. [DOI: 10.1002/jso.27134] [Reference Citation Analysis]
2 Riesco-Martinez MC, Modrego A, Espinosa-Olarte P, La Salvia A, Garcia-Carbonero R. Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer: Lessons Learned and Future Perspectives. Curr Treat Options Oncol 2022. [PMID: 35980520 DOI: 10.1007/s11864-022-01008-5] [Reference Citation Analysis]
3 Sharma K, Malviya RK, Gupta V. Estimation of phytochemicals contents and in-vitro antioxidant activity of Opuntia ficus Indica fruit extract. IJPP 2022;9:81-86. [DOI: 10.18231/j.ijpp.2022.015] [Reference Citation Analysis]
4 Luo J, Zhong X, Peng Y, Hao C, Liang X, Yang Y, Shi X, Chen X, Yi X, Li X, Wu J, Li J, Xiao Q, Wu C, Lu R, Pan Y, Wang X, Fan J, Wang Y, Wang Y. Self-anti-angiogenesis nanoparticles enhance anti-metastatic-tumor efficacy of chemotherapeutics. Bioactive Materials 2022;13:179-90. [DOI: 10.1016/j.bioactmat.2021.10.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Diasio RB, Offer SM. Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy. Cancers 2022;14:3207. [DOI: 10.3390/cancers14133207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhao X, Zhang T, Yan Y, Liu F, Li C, Fan J, Pan Y, Li X, Wang Y. Notch signaling regulates vessel structure and function via Hspg2. Gene 2022;826:146439. [PMID: 35339643 DOI: 10.1016/j.gene.2022.146439] [Reference Citation Analysis]
7 Deming DA. Total Neoadjuvant Strategies for Locally Advanced Rectal Cancer. Advances in Oncology 2022;2:227-236. [DOI: 10.1016/j.yao.2022.02.014] [Reference Citation Analysis]
8 González NS, Ros Montaña FJ, Illescas DG, Argota IB, Ballabrera FS, Élez Fernández ME. New Insights into Adjuvant Therapy for Localized Colon Cancer. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2022.02.006] [Reference Citation Analysis]
9 Rodriguez GV, Juvera Avalos ER, Gonzalez C, Barba de la Rosa AP, De Leon-rodriguez A. Production and optimization of a vasostatin-30 and vasoinhibin fusion protein that inhibits tumor angiogenesis and dissemination of breast cancer cells in a zebrafish model. Process Biochemistry 2022. [DOI: 10.1016/j.procbio.2022.05.002] [Reference Citation Analysis]
10 Patil V, Noronha V, Joshi A, Menon N, Mathrudev V, Bhattacharjee A, Chandrasekharan A, Vallathol D, Dsouza H, Srinivas S, Mandal T, Chaturvedi P, Chaukar D, Pai P, Nair S, Thiagrajan S, Laskar S, Nawale K, Babanrao Dhumal S, Tambe R, Banavali S, Prabhash K. RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation. Oral Oncology 2022;128:105816. [DOI: 10.1016/j.oraloncology.2022.105816] [Reference Citation Analysis]
11 Li X, Jonnagaddala J, Yang S, Zhang H, Xu XS. A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer. J Cancer Res Clin Oncol 2022. [PMID: 35332389 DOI: 10.1007/s00432-022-03976-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sakata S, Larson DW. Targeted Therapy for Colorectal Cancer. Surgical Oncology Clinics of North America 2022. [DOI: 10.1016/j.soc.2021.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Asgharzadeh F, Mostafapour A, Ebrahimi S, Amerizadeh F, Sabbaghzadeh R, Hassanian SM, Fakhraei M, Farshbaf A, Ferns GA, Giovannetti E, Avan A, Khazaei M. Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer. Toxicology and Applied Pharmacology 2022. [DOI: 10.1016/j.taap.2022.115951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Asada Y, Chinen K, Yamataka K, Tokuyama J, Kurihara N, Iida S. Pathological complete response after neoadjuvant chemotherapy with FOLFOX for locally advanced sigmoid colon cancer with diverticulitis: A case report. International Journal of Surgery Case Reports 2022;90:106685. [DOI: 10.1016/j.ijscr.2021.106685] [Reference Citation Analysis]
15 Kleiman DA, Larson DW. Colorectal Cancer: Postoperative Adjuvant Therapy and Surveillance. The ASCRS Textbook of Colon and Rectal Surgery 2022. [DOI: 10.1007/978-3-030-66049-9_30] [Reference Citation Analysis]
16 Daemen A, Udyavar AR, Sandmann T, Li C, Bosch LJW, O'Gorman W, Li Y, Au-Yeung A, Takahashi C, Kabbarah O, Bourgon R, Hegde P, Bais C, Das Thakur M. Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B. PLoS One 2021;16:e0262198. [PMID: 34972191 DOI: 10.1371/journal.pone.0262198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Morris V. Adjuvant Systemic Chemotherapy. Colorectal Liver Metastasis 2022. [DOI: 10.1007/978-3-031-09323-4_34] [Reference Citation Analysis]
18 Petrioli R, Miano ST, Martellucci I. Antiangiogenic agents in the treatment of colorectal, gastric, and gastroesophageal junction adenocarcinoma. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy 2022. [DOI: 10.1016/b978-0-323-90190-1.00007-x] [Reference Citation Analysis]
19 Zheng H, Mccombs JS, Barzi A. Provider imaging practices and outcomes of advanced colorectal cancer. Cancer Treatment and Research Communications 2022;32:100624. [DOI: 10.1016/j.ctarc.2022.100624] [Reference Citation Analysis]
20 Chen Y, Zheng X, Wu C. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. Front Immunol 2021;12:792691. [PMID: 34925375 DOI: 10.3389/fimmu.2021.792691] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
21 Yao Y, Liu Z, Zhang H, Li J, Peng Z, Yu J, Cao B, Shen L. Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis. Front Pharmacol 2021;12:754858. [PMID: 34867369 DOI: 10.3389/fphar.2021.754858] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Oneda E, Zaniboni A. Adjuvant treatment of colon cancer with microsatellite instability - the state of the art. Crit Rev Oncol Hematol 2021;169:103537. [PMID: 34801698 DOI: 10.1016/j.critrevonc.2021.103537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Li J, Xie Y, Huang Z, Shen D, Zhuang Z, Zhu M, Huang Y, He R, Wang X, Huang M, Luo Y, Yu H. Current treatment and surveillance modalities are not sufficient for advanced stage III colon cancer: Result from a multicenter cohort analysis. Cancer Med 2021. [PMID: 34786881 DOI: 10.1002/cam4.4417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Larribère L, Martens UM. Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors. Cancers (Basel) 2021;13:5698. [PMID: 34830853 DOI: 10.3390/cancers13225698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
25 Howe JR. The impact of DNA testing on management of patients with colorectal cancer. Ann Gastroenterol Surg. [DOI: 10.1002/ags3.12526] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
26 Maderer A, Fiteni F, Tanis E, Mauer M, Schmitt T, Aust DE, Lutz MP, Roelofson F, Gog C, Weinmann A, Koehne CH, Moehler M, Thomaidis T. CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset. Acta Oncol 2021;60:1543-7. [PMID: 34355650 DOI: 10.1080/0284186X.2021.1959057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lee HY, Woo IS. Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates. Cancers (Basel) 2021;13:4590. [PMID: 34572817 DOI: 10.3390/cancers13184590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Yin J, Salem ME, Dixon JG, Jin Z, Cohen R, De Gramont A, Van Cutsem E, Taieb J, Alberts SR, Wolmark N, Schmoll HJ, Saltz LB, George TJ, Goldberg RRM, Kerr R, Lonardi S, Yoshino T, Yothers G, Grothey A, Andre T, Shi Q. Re-Evaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. J Natl Cancer Inst 2021:djab187. [PMID: 34505880 DOI: 10.1093/jnci/djab187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Lam KO, Yip J, Law WL. Adjuvant Therapy options after Pelvic Exenteration for Advanced Rectal Cancer. Surgical Management of Advanced Pelvic Cancer 2021. [DOI: 10.1002/9781119518495.ch21] [Reference Citation Analysis]
30 Oki E, Ando K, Taniguchi H, Yoshino T, Mori M. Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer. Ann Gastroenterol Surg. [DOI: 10.1002/ags3.12503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Knapen DG, Cherny NI, Zygoura P, Latino NJ, Douillard JY, Dafni U, de Vries EGE, de Groot DJ. Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1. ESMO Open 2020;5:e000681. [PMID: 32893188 DOI: 10.1136/esmoopen-2020-000681] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
32 Zulkifli A, Tan FH, Areeb Z, Stuart SF, Gomez J, Paradiso L, Luwor RB. Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer. Int J Mol Sci 2021;22:7114. [PMID: 34281166 DOI: 10.3390/ijms22137114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Khan KA, Wu FT, Cruz-Munoz W, Kerbel RS. Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. EMBO Mol Med 2021;13:e08253. [PMID: 34125494 DOI: 10.15252/emmm.201708253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
34 Clark EH, Chiao EY. Malignancies in HIV. Fundamentals of HIV Medicine 2021 2021. [DOI: 10.1093/med/9780197576595.003.0036] [Reference Citation Analysis]
35 Treasure M, Thomas A, Ganocy S, Hong A, Krishnamurthi SS, Bajor DL, Berger NA, Meropol NJ. A pilot study of a low glycemic load diet in patients with stage I-III colorectal cancer. J Gastrointest Oncol 2021;12:910-20. [PMID: 34295544 DOI: 10.21037/jgo-20-330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Gambaro K, Marques M, McNamara S, Couetoux du Tertre M, Diaz Z, Hoffert C, Srivastava A, Hébert S, Samson B, Lespérance B, Ko YJ, Dalfen R, St-Hilaire E, Sideris L, Couture F, Burkes R, Harb M, Camlioglu E, Gologan A, Pelsser V, Constantin A, Greenwood CMT, Tejpar S, Kavan P, Kleinman CL, Batist G. Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer. Clin Transl Med 2021;11:e401. [PMID: 33931971 DOI: 10.1002/ctm2.401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
37 Kraeft A, Stein A, Modest D, Fichtner-feigl S, Tannapfel A, Reinacher-schick A. (Neo)adjuvante Behandlung beim frühen Kolonkarzinom. Onkologe 2021;27:245-258. [DOI: 10.1007/s00761-020-00876-6] [Reference Citation Analysis]
38 Herbrand AK, Schmitt AM, Briel M, Ewald H, Goldkuhle M, Diem S, Hoogkamer A, Joerger M, Moffa G, Novak U, Hemkens LG, Kasenda B. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. JAMA Netw Open 2021;4:e210380. [PMID: 33651108 DOI: 10.1001/jamanetworkopen.2021.0380] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Hansen TF, Qvortrup C, Pfeiffer P. Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers (Basel) 2021;13:1031. [PMID: 33804554 DOI: 10.3390/cancers13051031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
40 Lisby AN, Flickinger JC Jr, Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev 2021;6:117-29. [PMID: 34027103 DOI: 10.1080/23808993.2021.1876518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
41 Naidoo M, Gibbs P, Tie J. ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm. Cancers (Basel) 2021;13:346. [PMID: 33477814 DOI: 10.3390/cancers13020346] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
42 Qvortrup C, Pfeiffer P. Adjuvant Therapy in Patients with Colorectal Cancer. Multidisciplinary Treatment of Colorectal Cancer 2021. [DOI: 10.1007/978-3-030-58846-5_19] [Reference Citation Analysis]
43 Mohammadi Sepahvand E, Masoudnia M, Sadat Hosseininia H, Kazempour A, Bostanshirin N, Jalili A, Ebrahimi Sadrabadi A, Faculty of Veterinary Medicine, Karaj Branch, Islamic Azad University, Karaj, Iran, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Department of Cellular and Molecular Biology, Faculty of Advanced Medical Science, Tehran Islamic Azad University of Medical Sciences, Tehran, Iran, Department of Microbiology, Faculty of Science, Lahijan Branch, Islamic Azad University, Lahijan, Iran, Department of Microbiology, School of Medicine Science, Alborz University of Medical Science, Alborz, Iran, Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACER, Tehran, Iran.. Representing Tumor-Associated Macrophages as the Angiogenesis and Tumor Microenvironment Regulator. Mod Med Lab J 2021;4:52-67. [DOI: 10.30699/mmlj17.4.1.52] [Reference Citation Analysis]
44 Özenver N, Efferth T. Mitosis Inhibitors and Medicinal Plants: Neurotoxicity and Neuroprotection. Medicinal Herbs and Fungi 2021. [DOI: 10.1007/978-981-33-4141-8_1] [Reference Citation Analysis]
45 Unal OU, Keser M, Akagündüz B. Systemıc Chemotherapy in Colorectal Cancer. Colon Polyps and Colorectal Cancer 2021. [DOI: 10.1007/978-3-030-57273-0_34] [Reference Citation Analysis]
46 Cohen R, Taieb J, Fiskum J, Yothers G, Goldberg R, Yoshino T, Alberts S, Allegra C, de Gramont A, Seitz JF, O'Connell M, Haller D, Wolmark N, Erlichman C, Zaniboni A, Lonardi S, Kerr R, Grothey A, Sinicrope FA, André T, Shi Q. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol 2021;39:642-51. [PMID: 33356421 DOI: 10.1200/JCO.20.01600] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 17.5] [Reference Citation Analysis]
47 Fedyanin MY, Tryakin AA, Ter-ovanesov MD, Tyulyandin SA. DIAGNOSTICS, TREATMENT AND PROGNOSIS IN PATIENTS WITH COLORECTAL CANCER AND PERITONEAL CARCINOMATOSIS (review). Koloproktologiâ 2020;19:131-149. [DOI: 10.33878/2073-7556-2020-19-4-131-149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Alonso S, Saltz L. The Landmark Series: Chemotherapy for Non-Metastatic Colon Cancer. Ann Surg Oncol 2021;28:995-1001. [PMID: 33230749 DOI: 10.1245/s10434-020-09375-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
49 Leong A, Kim M. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer. Int J Mol Sci 2020;21:E8689. [PMID: 33217955 DOI: 10.3390/ijms21228689] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
50 Lee DW, Cho S, Shin A, Han SW, Kim TY. Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial. Sci Rep 2020;10:19467. [PMID: 33173165 DOI: 10.1038/s41598-020-76643-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
51 Hochster HS. Antiangiogenesis in Early-Stage Colon Cancer—Microscopically Busted. JAMA Netw Open 2020;3:e2021064. [DOI: 10.1001/jamanetworkopen.2020.21064] [Reference Citation Analysis]
52 Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, André T, de Gramont A. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial. JAMA Netw Open 2020;3:e2020425. [PMID: 33074326 DOI: 10.1001/jamanetworkopen.2020.20425] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
53 Skelton WP 4th, Franke AJ, Iqbal A, George TJ. Comprehensive literature review of randomized clinical trials examining novel treatment advances in patients with colon cancer. J Gastrointest Oncol 2020;11:790-802. [PMID: 32953161 DOI: 10.21037/jgo-20-184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
54 Taieb J, Gallois C. Adjuvant Chemotherapy for Stage III Colon Cancer. Cancers (Basel) 2020;12:E2679. [PMID: 32961795 DOI: 10.3390/cancers12092679] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
55 Chen J, Madireddi S, Nagarkar D, Migdal M, Vander Heiden J, Chang D, Mukhyala K, Selvaraj S, Kadel EE, Brauer MJ, Mariathasan S, Hunkapiller J, Jhunjhunwala S, Albert ML, Hammer C. In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales. Brief Bioinform 2021;22:bbaa223. [PMID: 32940337 DOI: 10.1093/bib/bbaa223] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
56 Liang J, Li Z, Li J, Peng C, Dai W, He H, Zeng S, Xie C. Application of IVIM-DWI in Detecting the Tumor Vasculogenic Mimicry Under Antiangiogenesis Combined With Oxaliplatin Treatment. Front Oncol 2020;10:1376. [PMID: 32974136 DOI: 10.3389/fonc.2020.01376] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
57 Chakrabarti S, Peterson CY, Sriram D, Mahipal A. Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World J Gastrointest Oncol 2020; 12(8): 808-832 [PMID: 32879661 DOI: 10.4251/wjgo.v12.i8.808] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
58 Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, Lorenc T. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers. Int J Mol Sci 2020;21:E5840. [PMID: 32823989 DOI: 10.3390/ijms21165840] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 25.5] [Reference Citation Analysis]
59 Rovers KP, Bakkers C, van Erning FN, Burger JWA, Nienhuijs SW, Simkens GAAM, Creemers GM, Hemmer PHJ, Punt CJA, Lemmens VEPP, Tanis PJ, de Hingh IHJT. Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases. JAMA Oncol 2020;6:e202701. [PMID: 32672798 DOI: 10.1001/jamaoncol.2020.2701] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
60 Rofeal M, El-malek FA. Valorization of Lipopeptides Biosurfactants as Anticancer Agents. Int J Pept Res Ther 2021;27:447-55. [DOI: 10.1007/s10989-020-10105-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
61 Gelsomino F, Spallanzani A, Casadei-Gardini A. Comment on Chun et al, "A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases". Clin Colorectal Cancer 2020;19:e262-3. [PMID: 32646655 DOI: 10.1016/j.clcc.2020.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Kraeft A, Reinacher-schick A, Folprecht G. Adjuvante Therapie des kolorektalen Karzinoms. Gastroenterologe 2020;15:290-299. [DOI: 10.1007/s11377-020-00453-8] [Reference Citation Analysis]
63 Yang Y, Ma L, Xu Y, Liu Y, Li W, Cai J, Zhang Y. Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. Cell Death Dis 2020;11:477. [PMID: 32581212 DOI: 10.1038/s41419-020-2675-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
64 Frentzas S, Lum C, Chen T. Angiogenesis and Its Role in the Tumour Microenvironment: A Target for Cancer Therapy. Current Cancer Treatment 2020. [DOI: 10.5772/intechopen.89667] [Reference Citation Analysis]
65 Chen J, Wang J, Ni T, He H, Zheng Q. Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma. Medicine (Baltimore) 2020;99:e19908. [PMID: 32569154 DOI: 10.1097/MD.0000000000019908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Sclafani F, Hendlisz A. Editorial: Adjuvant chemotherapy for gastrointestinal cancers: we can do much better. Curr Opin Oncol 2020;32:344-6. [PMID: 32541323 DOI: 10.1097/CCO.0000000000000638] [Reference Citation Analysis]
67 Batra A, Rigo R, Sheka D, Cheung WY. Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer. World J Gastrointest Oncol 2020; 12(6): 604-618 [PMID: 32699576 DOI: 10.4251/wjgo.v12.i6.604] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
68 Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, André T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol 2019;30:1466-71. [PMID: 31268130 DOI: 10.1093/annonc/mdz208] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 32.5] [Reference Citation Analysis]
69 Komorowski AS, MacKay HJ, Pezo RC. Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. Cancer Med 2020;9:5035-50. [PMID: 32452660 DOI: 10.1002/cam4.3095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Giampieri R, Ziranu P, Daniele B, Zizzi A, Ferrari D, Lonardi S, Zaniboni A, Cavanna L, Rosati G, Casagrande M, Pella N, Demurtas L, Zampino MG, Sozzi P, Pusceddu V, Germano D, Lai E, Zagonel V, Codecà C, Libertini M, Puzzoni M, Labianca R, Cascinu S, Scartozzi M. From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. Cancers (Basel) 2020;12:E1330. [PMID: 32456056 DOI: 10.3390/cancers12051330] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
71 Aomatsu N, Uchima Y, Tsujio G, Miyamoto Y, Okada T, Kurihara S, Matsutani S, Hirakawa T, Iwauchi T, Morimoto J, Yamagata S, Nakazawa K, Nishii T, Tachimori A, Maeda K, Ikeda K, Takeuchi K. Postoperative Adjuvant Chemotherapy Regimen of CAPOX Combined With Ninjin'yoeito in an Elderly Patient With Stage III Colon Cancer: A Case Report. Front Nutr 2020;7:57. [PMID: 32426365 DOI: 10.3389/fnut.2020.00057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Chen J, Madireddi S, Nagarkar D, Migdal M, Heiden JV, Chang D, Mukhyala K, Selvaraj S, Kadel EE, Brauer MJ, Mariathasan S, Hunkapiller J, Jhunjhunwala S, Albert ML, Hammer C. In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales.. [DOI: 10.1101/2020.04.24.060459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Hampsch RA, Wells JD, Traphagen NA, McCleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD, Demidenko E, Huang YH, Marotti JD, Goen AE, Kinlaw WB, Miller TW. AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells. Clin Cancer Res 2020;26:3707-19. [PMID: 32321715 DOI: 10.1158/1078-0432.CCR-20-0269] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
74 Parsons S, Maldonado EB, Prasad V. Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non-Small Cell Lung Cancers. JAMA Netw Open 2020;3:e202488. [PMID: 32275321 DOI: 10.1001/jamanetworkopen.2020.2488] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
75 Palazzolo G, Mollica H, Lusi V, Rutigliani M, Di Francesco M, Pereira RC, Filauro M, Paleari L, DeCensi A, Decuzzi P. Modulating the Distant Spreading of Patient-Derived Colorectal Cancer Cells via Aspirin and Metformin. Transl Oncol 2020;13:100760. [PMID: 32247264 DOI: 10.1016/j.tranon.2020.100760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
76 Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, André T; ACCENT Group. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. Eur J Cancer 2020;130:63-71. [PMID: 32172199 DOI: 10.1016/j.ejca.2020.02.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
77 Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, Shamseddine A. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. Front Oncol 2020;10:221. [PMID: 32175278 DOI: 10.3389/fonc.2020.00221] [Cited by in Crossref: 121] [Cited by in F6Publishing: 138] [Article Influence: 60.5] [Reference Citation Analysis]
78 To YH, Lee M, Gibbs P, Tie J. Circulating tumour DNA in early stage colorectal cancer: can blood tell all? Ann Transl Med 2019;7:S358. [PMID: 32016076 DOI: 10.21037/atm.2019.09.55] [Reference Citation Analysis]
79 Akagi T, Inomata M. Essential advances in surgical and adjuvant therapies for colorectal cancer 2018-2019. Ann Gastroenterol Surg 2020;4:39-46. [PMID: 32021957 DOI: 10.1002/ags3.12307] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
80 Hampsch RA, Wells JD, Traphagen NA, Mccleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD, Demidenko E, Huang YH, Marotti JD, Kinlaw WB, Miller TW. AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells.. [DOI: 10.1101/2020.01.21.914382] [Reference Citation Analysis]
81 Petrillo A, Ferraro E, Ghidini M, Trapani D. An Introduction to the Current Management of Colorectal Cancer in the Era of Personalized Oncology. Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing 2020. [DOI: 10.1007/978-3-030-53821-7_1] [Reference Citation Analysis]
82 Polite B. Colon Cancer. Oncology in the Precision Medicine Era 2020. [DOI: 10.1007/978-3-030-31471-2_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Nguyen TQ, Bui TO, Tran PT, Tran VT, Nguyen VH, Chu QH, Bui TAT, Le NQ, Le VQ, Dao VT. Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer. Cancer Control 2019;26:1073274819864111. [PMID: 31317770 DOI: 10.1177/1073274819864111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
84 Chakravarthy AB, Zhao F, Meropol NJ, Flynn PJ, Wagner LI, Sloan J, Diasio RB, Mitchell EP, Catalano P, Giantonio BJ, Catalano RB, Haller DG, Awan RA, Mulcahy MF, O'Brien TE, Santala R, Cripps C, Weis JR, Atkins JN, Leichman CG, Petrelli NJ, Sinicrope FA, Brierley JD, Tepper JE, O'Dwyer PJ, Sigurdson ER, Hamilton SR, Cella D, Benson AB 3rd. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). Oncologist 2020;25:e798-807. [PMID: 31852811 DOI: 10.1634/theoncologist.2019-0437] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
85 Chan GHJ, Chee CE. Making sense of adjuvant chemotherapy in colorectal cancer. J Gastrointest Oncol 2019;10:1183-92. [PMID: 31949938 DOI: 10.21037/jgo.2019.06.03] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
86 Herbrand AK, Schmitt AM, Briel M, Diem S, Ewald H, Hoogkamer A, Joerger M, Mc Cord KA, Novak U, Sricharoenchai S, Hemkens LG, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open 2019;4:e000596. [PMID: 31803503 DOI: 10.1136/esmoopen-2019-000596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
87 Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2020;77:1745-70. [PMID: 31690961 DOI: 10.1007/s00018-019-03351-7] [Cited by in Crossref: 422] [Cited by in F6Publishing: 468] [Article Influence: 140.7] [Reference Citation Analysis]
88 Bender U, Rho YS, Barrera I, Aghajanyan S, Acoba J, Kavan P. Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions. Curr Oncol 2019;26:S43-52. [PMID: 31819709 DOI: 10.3747/co.26.5605] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
89 Liu Z, Zou Y, Rong Y, Shi X, Li C, Li C, Tian Y, Lin H, Liu M, Weng J, Liu T, Li X, Lei C, Li W, Zhou X. Intraoperative Chemotherapy with a Novel Regimen Improved the Therapeutic Outcomes of Colorectal Cancer. J Cancer 2019;10:5986-91. [PMID: 31762808 DOI: 10.7150/jca.35450] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
90 Shan Y, Gao Y, Jin W, Fan M, Wang Y, Gu Y, Shan C, Sun L, Li X, Yu B, Luo Q, Xu Q. Targeting HIBCH to reprogram valine metabolism for the treatment of colorectal cancer. Cell Death Dis 2019;10:618. [PMID: 31409769 DOI: 10.1038/s41419-019-1832-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
91 Herbrand A, Schmitt A, Briel M, Diem S, Ewald H, Hoogkamer A, Joerger M, Mc Cord K, Novak U, Sricharoenchai S, Hemkens L, Kasenda B. Contrasting Evidence to Reimbursement Reality for Off-label use (OLU) of Drug Treatments in Cancer Care – Rationale and Design of the CEIT-OLU-project.. [DOI: 10.1101/19003152] [Reference Citation Analysis]
92 Miller IS, Shiels LP, Conroy E, Connor K, Dicker P, Gallagher WM, Donovan NO, Kerbel RS, Crown J, Byrne AT. Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents. Sci Rep 2019;9:9204. [PMID: 31235775 DOI: 10.1038/s41598-019-45444-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
93 Greally M, Ilson DH. Duration of Adjuvant Chemotherapy in Colon Cancer: Current Standards and New Updates. Curr Colorectal Cancer Rep 2019;15:122-9. [DOI: 10.1007/s11888-019-00438-y] [Reference Citation Analysis]
94 Zunder S, van der Wilk P, Gelderblom H, Dekker T, Mancao C, Kiialainen A, Putter H, Tollenaar R, Mesker W. Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial. Cell Oncol (Dordr) 2019;42:717-25. [PMID: 31102145 DOI: 10.1007/s13402-019-00449-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
95 Hoehn RS, Smith JJ. Adjuvant Chemotherapy for Colon Cancer. Dis Colon Rectum 2019;62:274-8. [PMID: 30741766 DOI: 10.1097/DCR.0000000000001328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
96 Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG)., Dutch Colorectal Cancer Group (DCCG). Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer 2019;19:390. [PMID: 31023318 DOI: 10.1186/s12885-019-5545-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 63] [Article Influence: 17.7] [Reference Citation Analysis]
97 Napolitano V, Tamagnone L. Neuropilins Controlling Cancer Therapy Responsiveness. Int J Mol Sci 2019;20:E2049. [PMID: 31027288 DOI: 10.3390/ijms20082049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
98 Danielsen HE, Hveem TS, Domingo E, Pradhan M, Kleppe A, Syvertsen RA, Kostolomov I, Nesheim JA, Askautrud HA, Nesbakken A, Lothe RA, Svindland A, Shepherd N, Novelli M, Johnstone E, Tomlinson I, Kerr R, Kerr DJ. Prognostic markers for colorectal cancer: estimating ploidy and stroma. Ann Oncol. 2018;29:616-623. [PMID: 29293881 DOI: 10.1093/annonc/mdx794] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
99 Bogomolova I, Antoneeva I, Dolgova D. CLINICAL CHARACTERISTICS OF COLORECTAL CANCER IN PATIENTS WITH EGFR-SIGNALING PATHWAY GENE MUTATIONS. Ulyanovsk Medico-biological Journal 2019. [DOI: 10.34014/2227-1848-2019-1-60-67] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
100 Yeung AWK, Abdel-Daim MM, Abushouk AI, Kadonosono K. A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach. Naunyn Schmiedebergs Arch Pharmacol 2019;392:393-403. [PMID: 30826857 DOI: 10.1007/s00210-019-01629-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
101 Ishikawa T, Uetake H. Adjuvant Chemotherapy. Recent Advances in the Treatment of Colorectal Cancer 2019. [DOI: 10.1007/978-981-13-3050-6_8] [Reference Citation Analysis]
102 Muniz PC, Tadokoro H, De Mello RA, Forones NM. Colon Cancer. International Manual of Oncology Practice 2019. [DOI: 10.1007/978-3-030-16245-0_16] [Reference Citation Analysis]
103 Loft M, Jalali A, Gibbs P, Tie J, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia, The University of Melbourne, Parkville, Australia, Western Health, Footscray, Australia, Peter MacCallum Cancer Centre, Parkville, Australia. Circulating Tumor DNA in Colorectal Cancer—From Concept to Clinic. Oncology & Hematology Review (US) 2019;15:33. [DOI: 10.17925/ohr.2019.15.1.33] [Reference Citation Analysis]
104 Boland P, Gong J, Fakih M. Adjuvant Therapy for Colorectal Cancer. Textbook of Gastrointestinal Oncology 2019. [DOI: 10.1007/978-3-030-18890-0_7] [Reference Citation Analysis]
105 Glynne-jones R, Hall M. Chemotherapy and Biologic Therapy in Rectal Cancer: An Update. Comprehensive Rectal Cancer Care 2019. [DOI: 10.1007/978-3-319-98902-0_22] [Reference Citation Analysis]
106 Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. Mol Oncol. 2019;13:109-131. [PMID: 30520562 DOI: 10.1002/1878-0261.12417] [Cited by in Crossref: 196] [Cited by in F6Publishing: 214] [Article Influence: 49.0] [Reference Citation Analysis]
107 Tan FH, Putoczki TL, Lou J, Hinde E, Hollande F, Giraud J, Stylli SS, Paradiso L, Zhu HJ, Sieber OM, Luwor RB. Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth. Cancers (Basel) 2018;10:E526. [PMID: 30572654 DOI: 10.3390/cancers10120526] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
108 Wei J, Luo Y, Fu D. Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther 2018;11:9049-59. [PMID: 30588017 DOI: 10.2147/OTT.S186816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
109 Chen D, Zhao J, Cong W. Chinese Herbal Medicines Facilitate the Control of Chemotherapy-Induced Side Effects in Colorectal Cancer: Progress and Perspective. Front Pharmacol 2018;9:1442. [PMID: 30581388 DOI: 10.3389/fphar.2018.01442] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
110 Wu FTH, Xu P, Chow A, Man S, Krüger J, Khan KA, Paez-Ribes M, Pham E, Kerbel RS. Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. Br J Cancer 2019;120:196-206. [PMID: 30498230 DOI: 10.1038/s41416-018-0297-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
111 Wu Z, Deng Y. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis. Curr Treat Options Oncol 2018;19:77. [PMID: 30483908 DOI: 10.1007/s11864-018-0597-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
112 Dasari A, Grothey A, Kopetz S. Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. J Clin Oncol. 2018;36:JCO2018789032. [PMID: 30376428 DOI: 10.1200/jco.2018.78.9032] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
113 Moore A, Ulitsky O, Ben-Aharon I, Perl G, Kundel Y, Sarfaty M, Lewin R, Domachevsky L, Bernstine H, Groshar D, Wasserberg N, Kashtan H, Gordon N, Sulkes A, Brenner B. Early PET-CT in patients with pathological stage III colon cancer may improve their outcome: Results from a large retrospective study. Cancer Med 2018;7:5470-7. [PMID: 30350468 DOI: 10.1002/cam4.1818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
114 Koizumi M, Yamada T, Shinji S, Yokoyama Y, Takahashi G, Iwai T, Takeda K, Hara K, Ohta K, Uchida E, Yoshida H. Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer. In Vivo. 2018;32:937-943. [PMID: 29936483 DOI: 10.21873/invivo.11332] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
115 Ko AH. Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. Hepatobiliary Surg Nutr 2018;7:406-8. [PMID: 30498720 DOI: 10.21037/hbsn.2018.06.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther 2018;11:5059-74. [PMID: 30174444 DOI: 10.2147/OTT.S166151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
117 Alnimer Y, Hindi Z, Katato K. The Effect of Perioperative Bevacizumab on Disease-Free and Overall Survival in Locally Advanced HER-2 Negative Breast Cancer: A Meta-Analysis. Breast Cancer (Auckl) 2018;12:1178223418792250. [PMID: 30090017 DOI: 10.1177/1178223418792250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
118 Lapeyre-prost A, Taieb J. Cancer du côlon non métastatique : désescalade thérapeutique. Colon Rectum 2018;12:161-169. [DOI: 10.3166/cer-2018-0025] [Reference Citation Analysis]
119 Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 2018;36:2621-9. [PMID: 30040523 DOI: 10.1200/JCO.2018.79.2028] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
120 Domingo E, Camps C, Kaisaki PJ, Parsons MJ, Mouradov D, Pentony MM, Makino S, Palmieri M, Ward RL, Hawkins NJ, Gibbs P, Askautrud H, Oukrif D, Wang H, Wood J, Tomlinson E, Bark Y, Kaur K, Johnstone EC, Palles C, Church DN, Novelli M, Danielsen HE, Sherlock J, Kerr D, Kerr R, Sieber O, Taylor JC, Tomlinson I. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. Lancet Gastroenterol Hepatol. 2018;3:635-643. [PMID: 30042065 DOI: 10.1016/s2468-1253(18)30117-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 9.8] [Reference Citation Analysis]
121 Mountzios G. Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era? Transl Lung Cancer Res 2018;7:S179-82. [PMID: 29782560 DOI: 10.21037/tlcr.2018.03.24] [Reference Citation Analysis]
122 Zunder SM, van Pelt GW, Gelderblom HJ, Mancao C, Putter H, Tollenaar RA, Mesker WE. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. Br J Cancer 2018;119:164-9. [PMID: 29755119 DOI: 10.1038/s41416-018-0083-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
123 Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 2018;378:1177-88. [PMID: 29590544 DOI: 10.1056/NEJMoa1713709] [Cited by in Crossref: 484] [Cited by in F6Publishing: 514] [Article Influence: 121.0] [Reference Citation Analysis]
124 Yamashita K, Katada N, Hosoda K, Mieno H, Moriya H, Kikuchi S, Watanabe M. Lauren Histology and Lymphatic Permeation are Critical Prognostic Factors in Borrmann Type I Gastric Cancer. International Surgery 2018;103:95-104. [DOI: 10.9738/intsurg-d-15-00205.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
125 Kim BJ, Jeong JH, Kim JH, Kim HS, Jang HJ. The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review. Oncotarget 2017;8:31112-8. [PMID: 28415706 DOI: 10.18632/oncotarget.16091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
126 Hohenberger W. Colorectal cancer – heading to the future. Innovative Surgical Sciences 2018;3:1-2. [DOI: 10.1515/iss-2018-0007] [Reference Citation Analysis]
127 Wagle MC, Kirouac D, Klijn C, Liu B, Mahajan S, Junttila M, Moffat J, Merchant M, Huw L, Wongchenko M, Okrah K, Srinivasan S, Mounir Z, Sumiyoshi T, Haverty PM, Yauch RL, Yan Y, Kabbarah O, Hampton G, Amler L, Ramanujan S, Lackner MR, Huang SA. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis Oncol 2018;2:7. [PMID: 29872725 DOI: 10.1038/s41698-018-0051-4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 15.8] [Reference Citation Analysis]
128 Monzo M, Santasusagna S, Moreno I, Martinez F, Hernández R, Muñoz C, Castellano JJ, Moreno J, Navarro A. Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer. Oncotarget 2017;8:30859-69. [PMID: 28415718 DOI: 10.18632/oncotarget.16103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
129 Gyawali B, Pantziarka P, Crispino S, Bouche G. Does the oncology community have a rejection bias when it comes to repurposed drugs? Ecancermedicalscience 2018;12:ed76. [PMID: 29456622 DOI: 10.3332/ecancer.2018.ed76] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
130 Zeger EL, Goldberg RM. Adjuvant Chemotherapy. Surgical Techniques in Rectal Cancer 2018. [DOI: 10.1007/978-4-431-55579-7_6] [Reference Citation Analysis]
131 Malla S, Gangishetti U. Tyrosine Kinase Inhibitors and Their Clinical Prospective in Pancreatic Cancer. Role of Tyrosine Kinases in Gastrointestinal Malignancies 2018. [DOI: 10.1007/978-981-13-1486-5_5] [Reference Citation Analysis]
132 Dahan N, Magidey K, Shaked Y. Resistance to Inhibitors of Angiogenesis. Resistance to Targeted Anti-Cancer Therapeutics 2018. [DOI: 10.1007/978-3-319-67932-7_9] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
133 Uemura M, Kato T, Miyake M, Miyazaki M, Sekimoto M. Adjuvant Chemotherapy for Curatively Resected Colon Cancer. Journal of Japan Society of Coloproctology 2018;71:393-405. [DOI: 10.3862/jcoloproctology.71.393] [Reference Citation Analysis]
134 Uetake H, Yamauchi S, Sugihara K. The Role of Systemic Chemotherapy in Colorectal Cancer. Surgical Treatment of Colorectal Cancer 2018. [DOI: 10.1007/978-981-10-5143-2_30] [Reference Citation Analysis]
135 Comunanza V, Bussolino F. Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Front Cell Dev Biol 2017;5:101. [PMID: 29270405 DOI: 10.3389/fcell.2017.00101] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
136 Zhao F, Tian W, Zeng M, Xia J, Hu H, Hao X, Han L, Liu H, He Y, Zhu X, Liang L, Ao R, Wei M, Deng L, Wei Y. Apatinib alone or combined with radiotherapy in metastatic prostate cancer: Results from a pilot, multicenter study. Oncotarget 2017;8:110774-84. [PMID: 29340015 DOI: 10.18632/oncotarget.22719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
137 Zarrin B, Zarifi F, Vaseghi G, Javanmard SH. Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance. J Res Med Sci 2017;22:117. [PMID: 29184575 DOI: 10.4103/jrms.JRMS_182_17] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
138 Stragier E, Prenen H. Antiangiogenic therapies in colorectal cancer. memo 2017;10:213-7. [DOI: 10.1007/s12254-017-0359-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
139 Szaryńska M, Olejniczak A, Kobiela J, Spychalski P, Kmieć Z. Therapeutic strategies against cancer stem cells in human colorectal cancer. Oncol Lett 2017;14:7653-68. [PMID: 29250169 DOI: 10.3892/ol.2017.7261] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
140 Berlin JD, Feng Y, Catalano P, Abbruzzese JL, Philip PA, McWilliams RR, Lowy AM, Benson AB III, Blackstock AW. An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). Oncology 2018;94:39-46. [PMID: 29040974 DOI: 10.1159/000480295] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
141 Mitsis M, Koliou P, Bali C, Ntounousi E, Tatsis V, Nousias V, Lianos GD, Vartholomatos G, Nastos D. In Surgical Colon Cancer Patients Extended-Duration Thromboprophylaxis (30 days) with the Highest Dose of Tinzaparin (4,500 IU s.c./q.d.) Normalizes the Postoperative VEGF Levels. J Cancer 2017;8:2899-906. [PMID: 28928880 DOI: 10.7150/jca.20107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
142 Nitsche U, Stöss C, Friess H. Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence. Gastrointest Tumors 2017;4:11-9. [PMID: 29071260 DOI: 10.1159/000479318] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
143 Totzeck M, Mincu RI, Rassaf T. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients. J Am Heart Assoc 2017;6:e006278. [PMID: 28862931 DOI: 10.1161/JAHA.117.006278] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 14.8] [Reference Citation Analysis]
144 Zeng DX, Wang CG, Lei W, Huang JA, Jiang JH. Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. Oncotarget 2017;8:66248-53. [PMID: 29029508 DOI: 10.18632/oncotarget.19908] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
145 Chionh F, Lau D, Yeung Y, Price T, Tebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database Syst Rev 2017;7:CD008398. [PMID: 28752564 DOI: 10.1002/14651858.CD008398.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
146 Malesci A, Bianchi P, Celesti G, Basso G, Marchesi F, Grizzi F, Di Caro G, Cavalleri T, Rimassa L, Palmqvist R. Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. Oncoimmunology. 2017;6:e1342918. [PMID: 29209561 DOI: 10.1080/2162402x.2017.1342918] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 13.2] [Reference Citation Analysis]
147 Zhang Y, Sun M, Huang G, Yin L, Lai Q, Yang Y, Xing X, Yu G, Sun Y, Wang X, Nie G, Liu Y, Cao Y. Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy. Proc Natl Acad Sci U S A 2017;114:E5226-35. [PMID: 28607065 DOI: 10.1073/pnas.1705066114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
148 Li W, Li X, Liu S, Yang W, Pan F, Yang XY, Du B, Qin L, Pan Y. Gold nanoparticles attenuate metastasis by tumor vasculature normalization and epithelial-mesenchymal transition inhibition. Int J Nanomedicine 2017;12:3509-20. [PMID: 28496326 DOI: 10.2147/IJN.S128802] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
149 Mitani S, Muro K. No benefit from ramucirumab in first-line chemotherapy? Transl Gastroenterol Hepatol 2017;2:30. [PMID: 28529984 DOI: 10.21037/tgh.2017.03.18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
150 Cuyle PJ, Prenen H. Current and future biomarkers in the treatment of colorectal cancer. Acta Clin Belg 2017;72:103-15. [PMID: 27917697 DOI: 10.1080/17843286.2016.1262996] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
151 Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017;20:185-204. [PMID: 28361267 DOI: 10.1007/s10456-017-9552-y] [Cited by in Crossref: 320] [Cited by in F6Publishing: 355] [Article Influence: 64.0] [Reference Citation Analysis]
152 Yang WH, Xu J, Mu JB, Xie J. Revision of the concept of anti-angiogenesis and its applications in tumor treatment. Chronic Dis Transl Med 2017;3:33-40. [PMID: 29063054 DOI: 10.1016/j.cdtm.2017.01.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
153 Zhou L, Lan H, Zhou Q, Yue J, Liu B. Plasma angiopoietin-2 is persistently elevated after non-small cell lung cancer surgery and stimulates angiogenesis in vitro. Medicine (Baltimore). 2016;95:e4493. [PMID: 27512865 DOI: 10.1097/md.0000000000004493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
154 Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, Griffin SM, Mansoor W, Coxon FY, Falk SJ, Darby S, Sumpter KA, Blazeby JM, Langley RE. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017;18:357-70. [PMID: 28163000 DOI: 10.1016/S1470-2045(17)30043-8] [Cited by in Crossref: 174] [Cited by in F6Publishing: 189] [Article Influence: 34.8] [Reference Citation Analysis]
155 Simha V, Kapoor R, Sharma S. Multiple localized metachronous recurrences in a patient of colon cancer and therapeutic controversies in stage II colon cancer. Transl Gastroenterol Hepatol 2016;1:20. [PMID: 28138587 DOI: 10.21037/tgh.2016.03.05] [Reference Citation Analysis]
156 Ursem C, Van Loon K, Venook A. Adjuvant Therapy Trials. Cancer J 2016;22:196-8. [PMID: 27341598 DOI: 10.1097/PPO.0000000000000188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
157 Snoeren N, van Hillegersberg R, Schouten SB, Bergman AM, van Werkhoven E, Dalesio O, Tollenaar RA, Verheul HM, van der Sijp J, Borel Rinkes IH, Voest EE; Hepatica study group. Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study. Neoplasia 2017;19:93-9. [PMID: 28088688 DOI: 10.1016/j.neo.2016.08.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
158 Lupo G, Caporarello N, Olivieri M, Cristaldi M, Motta C, Bramanti V, Avola R, Salmeri M, Nicoletti F, Anfuso CD. Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine. Front Pharmacol. 2016;7:519. [PMID: 28111549 DOI: 10.3389/fphar.2016.00519] [Cited by in Crossref: 34] [Cited by in F6Publishing: 46] [Article Influence: 6.8] [Reference Citation Analysis]
159 Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79-92. [PMID: 28050011 DOI: 10.1038/nrc.2016.126] [Cited by in Crossref: 444] [Cited by in F6Publishing: 470] [Article Influence: 88.8] [Reference Citation Analysis]
160 Meyers BM, Cosby R, Quereshy F, Jonker D. Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline. Curr Oncol 2016;23:418-24. [PMID: 28050138 DOI: 10.3747/co.23.3330] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
161 Chan DLH, Espinoza D, Chan J, Lee A, Faisal W, Segelov E, Pavlakis N. Adjuvant anti-VEGF therapy for overall survival and relapse-free survival in patients with resected non-metastatic colorectal cancer. Cochrane Database of Systematic Reviews 2016. [DOI: 10.1002/14651858.cd012460] [Reference Citation Analysis]
162 Kumar S, Noel MS, Khorana AA. Advances in adjuvant therapy of colon cancer. Seminars in Colon and Rectal Surgery 2016;27:204-212. [DOI: 10.1053/j.scrs.2016.04.019] [Reference Citation Analysis]
163 Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist. 2016;21:1509-1521. [PMID: 27881709 DOI: 10.1634/theoncologist.2016-0153] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
164 Bertucci F, Goncalves A, Viens P. Bevacizumab in HER2-negative inflammatory breast cancer. Oncoscience 2016;3:297-8. [PMID: 28105446 DOI: 10.18632/oncoscience.324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
165 Wu FT, Paez-Ribes M, Xu P, Man S, Bogdanovic E, Thurston G, Kerbel RS. Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. Sci Rep 2016;6:36694. [PMID: 27841282 DOI: 10.1038/srep36694] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
166 Chan J. Oncological management of colorectal liver metastases in the era of minimal access surgery. Laparoscopic Liver, Pancreas, and Biliary Surgery 2016. [DOI: 10.1002/9781118781166.ch13] [Reference Citation Analysis]
167 Algül H, Schmid RM. Adjuvante Therapie des Kolonkarzinoms. Gastroenterologe 2016;11:456-463. [DOI: 10.1007/s11377-016-0109-1] [Reference Citation Analysis]
168 Fontana E, Homicsko K, Eason K, Sadanandam A. Molecular Classification of Colon Cancer: Perspectives for Personalized Adjuvant Therapy. Curr Colorectal Cancer Rep 2016;12:296-302. [DOI: 10.1007/s11888-016-0341-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
169 Shi Q, Sargent DJ, Renfro LA. Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the Power of Pooled Individual Patient Data from Multiple Clinical Trials. Curr Colorectal Cancer Rep 2016;12:251-259. [DOI: 10.1007/s11888-016-0331-8] [Reference Citation Analysis]
170 Wu FT, Man S, Xu P, Chow A, Paez-Ribes M, Lee CR, Pirie-Shepherd SR, Emmenegger U, Kerbel RS. Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. Cancer Res 2016;76:6988-7000. [PMID: 27651308 DOI: 10.1158/0008-5472.CAN-16-0888] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
171 Pinto MP, Sotomayor P, Carrasco-Avino G, Corvalan AH, Owen GI. Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells. Int J Mol Sci 2016;17:E1489. [PMID: 27608016 DOI: 10.3390/ijms17091489] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 6.8] [Reference Citation Analysis]
172 Sievers CK, Kratz JD, Zurbriggen LD, LoConte NK, Lubner SJ, Uboha N, Mulkerin D, Matkowskyj KA, Deming DA. The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms. Clin Colon Rectal Surg 2016;29:232-8. [PMID: 27582648 DOI: 10.1055/s-0036-1584292] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
173 Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World J Hepatol 2016; 8(23): 957-960 [PMID: 27621761 DOI: 10.4254/wjh.v8.i23.957] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
174 Steeg PS. Targeting metastasis. Nat Rev Cancer 2016;16:201-18. [PMID: 27009393 DOI: 10.1038/nrc.2016.25] [Cited by in Crossref: 837] [Cited by in F6Publishing: 886] [Article Influence: 139.5] [Reference Citation Analysis]
175 Zhang M, Xiao B, Wang H, Han MK, Zhang Z, Viennois E, Xu C, Merlin D. Edible Ginger-derived Nano-lipids Loaded with Doxorubicin as a Novel Drug-delivery Approach for Colon Cancer Therapy. Mol Ther 2016;24:1783-96. [PMID: 27491931 DOI: 10.1038/mt.2016.159] [Cited by in Crossref: 121] [Cited by in F6Publishing: 130] [Article Influence: 20.2] [Reference Citation Analysis]
176 Innominato PF, Adam R. Use of Bevacizumab in the Management of Potentially Resectable Colorectal Liver Metastases: Safety, Pathologic Assessment and Benefit. Curr Colorectal Cancer Rep 2016;12:208-216. [DOI: 10.1007/s11888-016-0326-5] [Reference Citation Analysis]
177 Dai L, Cui X, Zhang X, Cheng L, Liu Y, Yang Y, Fan P, Wang Q, Lin Y, Zhang J, Li C, Mao Y, Wang Q, Su X, Zhang S, Peng Y, Yang H, Hu X, Yang J, Huang M, Xiang R, Yu D, Zhou Z, Wei Y, Deng H. SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin. Nat Commun 2016;7:11996. [PMID: 27353863 DOI: 10.1038/ncomms11996] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 11.5] [Reference Citation Analysis]
178 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
179 Cui C, Qi J, Deng Q, Chen R, Zhai D, Yu J. Nicotinamide Mononucleotide Adenylyl Transferase 2: A Promising Diagnostic and Therapeutic Target for Colorectal Cancer. Biomed Res Int 2016;2016:1804137. [PMID: 27218101 DOI: 10.1155/2016/1804137] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
180 Shaked Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol 2016;13:611-26. [PMID: 27118493 DOI: 10.1038/nrclinonc.2016.57] [Cited by in Crossref: 86] [Cited by in F6Publishing: 89] [Article Influence: 14.3] [Reference Citation Analysis]
181 Shen Y, Han X, Wang J, Wang S, Yang H, Lu SH, Shi Y. Prognostic impact of mutation profiling in patients with stage II and III colon cancer. Sci Rep 2016;6:24310. [PMID: 27074743 DOI: 10.1038/srep24310] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
182 Aoyama T, Yoshikawa T. Targeted therapy: Apatinib - new third-line option for refractory gastric or GEJ cancer. Nat Rev Clin Oncol 2016;13:268-70. [PMID: 27071350 DOI: 10.1038/nrclinonc.2016.53] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
183 Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385-403. [PMID: 26775688 DOI: 10.1038/nrd.2015.17] [Cited by in Crossref: 527] [Cited by in F6Publishing: 562] [Article Influence: 87.8] [Reference Citation Analysis]
184 Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall’Olio FG, Barbera MA, Pantaleo MA, Biasco G. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World J Gastroenterol 2016; 22(2): 519-533 [PMID: 26811604 DOI: 10.3748/wjg.v22.i2.519] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 55] [Article Influence: 8.2] [Reference Citation Analysis]
185 Kelley RK. Adjuvant sorafenib for liver cancer: wrong stage, wrong dose. Lancet Oncol 2015;16:1279-81. [PMID: 26433814 DOI: 10.1016/S1470-2045(15)00296-X] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
186 Czito BG, Hsu D, Palta M, Willett CG. Colon Cancer. Clinical Radiation Oncology 2016. [DOI: 10.1016/b978-0-323-24098-7.00050-2] [Reference Citation Analysis]
187 Sentovich SM, Fakih M. Colorectal Cancer: Postoperative Adjuvant Therapy. The ASCRS Textbook of Colon and Rectal Surgery 2016. [DOI: 10.1007/978-3-319-25970-3_33] [Reference Citation Analysis]
188 Kim JH, Baek MJ, Ahn BK, Kim DD, Kim IY, Kim JS, Bae BN, Seo BG, Jung SH, Hong KH, Kim H, Park DG, Lee JH. Clinical Practice in the Use of Adjuvant Chemotherapy for Patients with Colon Cancer in South Korea: a Multi-Center, Prospective, Observational Study. J Cancer 2016;7:136-43. [PMID: 26819636 DOI: 10.7150/jca.13405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
189 Kawakami H, Zaanan A, Sinicrope FA. Implications of mismatch repair-deficient status on management of early stage colorectal cancer. J Gastrointest Oncol. 2015;6:676-684. [PMID: 26697201 DOI: 10.3978/j.issn.2078-6891.2015.065] [Cited by in F6Publishing: 33] [Reference Citation Analysis]
190 Morris V, Qiao W, Kopetz S. BRAF Mutations in Non-Metastatic Colorectal Cancer: Current Relevance and Future Implications. Curr Colorectal Cancer Rep 2015;11:303-310. [DOI: 10.1007/s11888-015-0295-0] [Reference Citation Analysis]
191 Margalit O, Dubois RN. Neoplasia of the Gastrointestinal Tract. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch31] [Reference Citation Analysis]
192 Luther J, Chan AT. Malignant Tumors of the Colon. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch78] [Reference Citation Analysis]
193 Mross K. Addition von Ramucirumab zu FOLFIRI in der Zweitlinie. Info Onkol 2015;18:22-24. [DOI: 10.1007/s15004-015-0982-7] [Reference Citation Analysis]
194 Sweeney L, Adams R. Management of cancer of the colon and rectum. Practical Clinical Oncology 2015. [DOI: 10.1017/cbo9781107280250.018] [Reference Citation Analysis]
195 Glynne-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, MacDonald A, Osborne M, Beare S, Jitlal M, Lopes A, Hall M, West N, Quirke P, Wong WL, Harrison M;  Bacchus investigators. Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. BMC Cancer. 2015;15:764. [PMID: 26493588 DOI: 10.1186/s12885-015-1764-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
196 Lee DW, Han SW, Cha Y, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Park JW, Ryoo SB, Jeong SY, Kang GH, Park KJ, Kim TY. Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. BMC Cancer 2015;15:690. [PMID: 26467912 DOI: 10.1186/s12885-015-1704-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
197 Iacovelli R, Pietrantonio F, Palazzo A, Maggi C, Ricchini F, de Braud F, Di Bartolomeo M. Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol 2014;78:1228-37. [PMID: 24962653 DOI: 10.1111/bcp.12449] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
198 Ciombor KK, Goldberg RM. Update on Anti-Angiogenesis Therapy in Colorectal Cancer. Curr Colorectal Cancer Rep 2015;11:378-87. [PMID: 27551256 DOI: 10.1007/s11888-015-0292-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
199 Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One 2015;10:e0136324. [PMID: 26331473 DOI: 10.1371/journal.pone.0136324] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
200 ElHalawani H, Abdel-Rahman O. Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers. Ther Clin Risk Manag. 2015;11:1123-1132. [PMID: 26251608 DOI: 10.2147/tcrm.s71045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
201 Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol Med 2014;6:1561-76. [PMID: 25361689 DOI: 10.15252/emmm.201403989] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
202 Pak KH, Jo A, Choi HJ, Choi Y, Kim H, Cheong JH. The different role of intratumoral and peritumoral lymphangiogenesis in gastric cancer progression and prognosis. BMC Cancer 2015;15:498. [PMID: 26141595 DOI: 10.1186/s12885-015-1501-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
203 Parnaby CN, Scott NW, Ramsay G, MacKay C, Samuel L, Murray GI, Loudon MA. Prognostic value of lymph node ratio and extramural vascular invasion on survival for patients undergoing curative colon cancer resection. Br J Cancer 2015;113:212-9. [PMID: 26079302 DOI: 10.1038/bjc.2015.211] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
204 Jeong HS, Jones D, Liao S, Wattson DA, Cui CH, Duda DG, Willett CG, Jain RK, Padera TP. Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. J Natl Cancer Inst 2015;107:djv155. [PMID: 26063793 DOI: 10.1093/jnci/djv155] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 11.0] [Reference Citation Analysis]
205 Suenaga M, Fujimoto Y, Matsusaka S, Shinozaki E, Akiyoshi T, Nagayama S, Fukunaga Y, Oya M, Ueno M, Mizunuma N, Yamaguchi T. Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). Onco Targets Ther 2015;8:1111-8. [PMID: 26056475 DOI: 10.2147/OTT.S83952] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
206 Pectasides D, Karavasilis V, Papaxoinis G, Gourgioti G, Makatsoris T, Raptou G, Vrettou E, Sgouros J, Samantas E, Basdanis G, Papakostas P, Bafaloukos D, Kotoula V, Kalofonos HP, Scopa CD, Pentheroudakis G, Fountzilas G. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer. BMC Cancer 2015;15:384. [PMID: 25956750 DOI: 10.1186/s12885-015-1406-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
207 Huiskens J, van Gulik TM, van Lienden KP, Engelbrecht MR, Meijer GA, van Grieken NC, Schriek J, Keijser A, Mol L, Molenaar IQ, Verhoef C, de Jong KP, Dejong KH, Kazemier G, Ruers TM, de Wilt JH, van Tinteren H, Punt CJ. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer 2015;15:365. [PMID: 25943574 DOI: 10.1186/s12885-015-1323-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
208 Qu CY, Zheng Y, Zhou M, Zhang Y, Shen F, Cao J, Xu LM. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. World J Gastroenterol 2015; 21(16): 5072-5080 [PMID: 25945023 DOI: 10.3748/wjg.v21.i16.5072] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 51] [Article Influence: 6.7] [Reference Citation Analysis]
209 Oba MS, Teramukai S, Ohashi Y, Ogawa K, Maehara Y, Sakamoto J. The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials. Gastric Cancer 2016;19:616-24. [PMID: 25804300 DOI: 10.1007/s10120-015-0489-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
210 Arimoto A, Uehara K, Tsuzuki T, Aiba T, Ebata T, Nagino M. Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer. Int J Clin Oncol 2015;20:935-42. [PMID: 25788218 DOI: 10.1007/s10147-015-0818-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
211 Aspinall SL, Good CB, Zhao X, Cunningham FE, Heron BB, Geraci M, Passero V, Stone RA, Smith KJ, Rogers R, Shields J, Sartore M, Boyle DP, Giberti S, Szymanski J, Smith D, Ha A, Sessions J, Depcinski S, Fishco S, Molina I, Lepir T, Jean C, Cruz-Diaz L, Motta J, Calderon-Vargas R, Maland J, Keefe S, Tague M, Leone A, Glovack B, Kaplan B, Cosgriff S, Kaster L, Tonnu-Mihara I, Nguyen K, Carmichael J, Clifford L, Lu K, Chatta G. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer 2015;15:62. [PMID: 25884851 DOI: 10.1186/s12885-015-1038-y] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
212 Jones RG, Tan D. How can we determine the best neoadjuvant chemoradiotherapy regimen for rectal cancer? Colorectal Cancer 2015;4:37-52. [DOI: 10.2217/crc.15.3] [Reference Citation Analysis]
213 Haller DG, O'Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, Saif MW, Lee S, Yothers G, Schmoll HJ. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol. 2015;26:715-724. [PMID: 25595934 DOI: 10.1093/annonc/mdv003] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 10.7] [Reference Citation Analysis]
214 Russo A, Galvano A, Bronte G, Peeters M. Targeted Therapies for Colorectal Cancer. Current Clinical Pathology 2015. [DOI: 10.1007/978-1-4939-2047-1_13] [Reference Citation Analysis]
215 Mathonnet M, Perraud A, Blondy S, Christou N, Akil H, Battu S, Jauberteau MO. Cancer Stem Cell Niche. Stem Cell Biology and Regenerative Medicine 2015. [DOI: 10.1007/978-3-319-21702-4_9] [Reference Citation Analysis]
216 Dahl O, Pfeffer F. Twenty-five years with adjuvant chemotherapy for colon cancer--a continuous evolving concept. Acta Oncol 2015;54:1-4. [PMID: 25263079 DOI: 10.3109/0284186X.2014.958533] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
217 Sze WM. Updates in Adjuvant Therapy. Minimally Invasive Coloproctology 2015. [DOI: 10.1007/978-3-319-19698-5_23] [Reference Citation Analysis]
218 Baguley BC, Mckeage MJ. Therapeutic targeting of tumor angiogenesis: how far have we come? Clinical Investigation 2014;4:1113-1122. [DOI: 10.4155/cli.14.91] [Reference Citation Analysis]
219 Taieb J. Traitement adjuvant : mise au point stades II, stades III, sujets âgés, biothérapies. Oncologie 2014;16:504-508. [DOI: 10.1007/s10269-014-2461-4] [Reference Citation Analysis]
220 Loffeld RJ, Flens M, Fransen G, den Boer FC, van Bochove A. The localisation of cancer in the sigmoid, rectum or rectosigmoid junction using endoscopy or radiology-What is the most accurate method? J Gastrointest Oncol 2014;5:469-73. [PMID: 25436127 DOI: 10.3978/j.issn.2078-6891.2014.087] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
221 Sibertin-blanc C, Dahan L, Michel P, Seitz J. Traitement adjuvant du cancer colorectal : l’aspirine, une biothérapie ciblée ? Oncologie 2014;16:509-515. [DOI: 10.1007/s10269-014-2463-2] [Reference Citation Analysis]
222 Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncol 2014;15:1481-92. [PMID: 25456367 DOI: 10.1016/S1470-2045(14)70486-3] [Cited by in Crossref: 113] [Cited by in F6Publishing: 98] [Article Influence: 14.1] [Reference Citation Analysis]
223 Renfro LA, Grothey A, Xue Y, Saltz LB, André T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group. ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst 2014;106:dju333. [PMID: 25359867 DOI: 10.1093/jnci/dju333] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]
224 Ferraro D, Zalcberg J. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. Ther Adv Med Oncol. 2014;6:222-228. [PMID: 25342989 DOI: 10.1177/1758834014544892] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
225 Gill S. Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies. Indian J Med Paediatr Oncol. 2014;35:197-202. [PMID: 25336789 DOI: 10.4103/0971-5851.142032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
226 Javle M, Smyth EC, Chau I. Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res 2014;20:5875-81. [PMID: 25281695 DOI: 10.1158/1078-0432.CCR-14-1071] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
227 Thomaidis T, Maderer A, Formentini A, Bauer S, Trautmann M, Schwarz M, Neumann W, Kittner JM, Schad A, Link KH, Rey JW, Weinmann A, Hoffman A, Galle PR, Kornmann M, Moehler M. Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial. J Exp Clin Cancer Res 2014;33:83. [PMID: 25272957 DOI: 10.1186/s13046-014-0083-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
228 Trédan O, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barrière J, Bidard FC, Braccini AL, Mir O, Villanueva C, Barthélémy P. Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. Target Oncol 2015;10:189-98. [PMID: 25185646 DOI: 10.1007/s11523-014-0334-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
229 de Gramont A, Chibaudel B, Perez-staub N, Dumont S, Larsen AK, André T. Accuracy of Predefined Hypotheses in Colon Cancer Adjuvant Phase III Trials: Observations and Recommendations. Curr Colorectal Cancer Rep 2014;10:329-338. [DOI: 10.1007/s11888-014-0229-2] [Reference Citation Analysis]
230 Turan N, Benekli M, Dane F, Unal OU, Kara HV, Koca D, Balvan O, Eren T, Tastekin D, Helvaci K, Berk V, Demirci U, Ozturk SC, Dogan E, Cetin B, Kucukoner M, Tonyali O, Tufan G, Oztop I, Gumus M, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. Thorac Cancer 2014;5:398-404. [PMID: 26763794 DOI: 10.1111/1759-7714.12107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
231 Russell JS, Brown JM. Circulating mouse Flk1+/c-Kit+/CD45- cells function as endothelial progenitors cells (EPCs) and stimulate the growth of human tumor xenografts. Mol Cancer 2014;13:177. [PMID: 25047738 DOI: 10.1186/1476-4598-13-177] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
232 Stein A, Bokemeyer C. Neue Substanzen für die Therapie solider Tumoren. Forum 2014;29:300-304. [DOI: 10.1007/s12312-014-1160-9] [Reference Citation Analysis]
233 Zaanan A, Bachet JB, André T, Sinicrope FA. Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAFV600E in Patients with Lymph Node-Positive Colon Cancer. Curr Colorectal Cancer Rep 2014;10:346-53. [PMID: 25386108 DOI: 10.1007/s11888-014-0237-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
234 Akhtar R, Chandel S, Sarotra P, Medhi B. Current status of pharmacological treatment of colorectal cancer. World J Gastrointest Oncol 2014; 6(6): 177-183 [PMID: 24936228 DOI: 10.4251/wjgo.v6.i6.177] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
235 Binefa G, Rodríguez-Moranta F, Teule &, Medina-Hayas M. Colorectal cancer: From prevention to personalized medicine. World J Gastroenterol 2014; 20(22): 6786-6808 [PMID: 24944469 DOI: 10.3748/wjg.v20.i22.6786] [Cited by in CrossRef: 202] [Cited by in F6Publishing: 215] [Article Influence: 25.3] [Reference Citation Analysis]
236 Qi WX, Shen Z, Tang LN, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol. 2014;70:893-906. [PMID: 24858820 DOI: 10.1007/s00228-014-1687-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
237 Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, Xu JM. Anti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases. World J Gastroenterol 2014; 20(15): 4263-4275 [PMID: 24764664 DOI: 10.3748/wjg.v20.i15.4263] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
238 Mathonnet M, Perraud A, Christou N, Akil H, Melin C, Battu S, Jauberteau MO, Denizot Y. Hallmarks in colorectal cancer: Angiogenesis and cancer stem-like cells. World J Gastroenterol 2014; 20(15): 4189-4196 [PMID: 24764657 DOI: 10.3748/wjg.v20.i15.4189] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 65] [Article Influence: 8.1] [Reference Citation Analysis]
239 Briggs S, Midgley R. Antiangiogenesis: focus on colorectal cancer. Antiangiogenesis in Cancer Therapy 2014. [DOI: 10.2217/ebo.13.635] [Reference Citation Analysis]
240 Leiter A, Galsky MD. Targeting vascular endothelial growth factor receptor signaling in renal cancer: the sooner the better? Eur Urol 2014;66:881-3. [PMID: 24631407 DOI: 10.1016/j.eururo.2014.02.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
241 Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 2014;9:e89960. [PMID: 24599121 DOI: 10.1371/journal.pone.0089960] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
242 Staal S, Daily K, Allegra C. Controversies in Adjuvant Chemotherapy. Colorectal Cancer 2014. [DOI: 10.1002/9781118337929.ch10] [Reference Citation Analysis]
243 Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471-94. [PMID: 24482243 DOI: 10.1007/s10456-014-9420-y] [Cited by in Crossref: 474] [Cited by in F6Publishing: 430] [Article Influence: 59.3] [Reference Citation Analysis]
244 Maile MM, Wong EY, Suzin D, Birrer NE, Penson RT. Discovery and Development of Antiangiogenetic Drugs in Ovarian Cancer. Anti-Angiogenesis Drug Discovery and Development 2014. [DOI: 10.1016/b978-0-12-803963-2.50006-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
245 Eveno C, Pocard M. Anti-angiogenic Therapies in Colorectal Cancer. Molecular Mechanisms of Angiogenesis 2014. [DOI: 10.1007/978-2-8178-0466-8_19] [Reference Citation Analysis]
246 Davar D, Sun W. Immunotherapy for Gastrointestinal Malignancies. JCT 2014;05:622-646. [DOI: 10.4236/jct.2014.56072] [Reference Citation Analysis]
247 Saavedra E, Hollebecque A, Soria JC, Hartl DM. Dysphonia induced by anti-angiogenic compounds. Invest New Drugs 2014;32:774-82. [PMID: 24343672 DOI: 10.1007/s10637-013-0049-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
248 Palta M, Willett C, Czito B. Current options in chemoradiotherapy for rectal cancer. Colorectal Cancer 2013;2:459-465. [DOI: 10.2217/crc.13.50] [Reference Citation Analysis]
249 Luu C, Arrington AK, Schoellhammer HF, Singh G, Kim J. Targeted therapies in colorectal cancer: surgical considerations. J Gastrointest Oncol 2013;4:328-36. [PMID: 23997944 DOI: 10.3978/j.issn.2078-6891.2013.032] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
250 Glynne-Jones R, Hadaki M, Harrison M. The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. J Gastrointest Oncol 2013;4:264-84. [PMID: 23997939 DOI: 10.3978/j.issn.2078-6891.2013.037] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
251 Nelson VM, Benson AB 3rd. Status of targeted therapies in the adjuvant treatment of colon cancer. J Gastrointest Oncol 2013;4:245-52. [PMID: 23997937 DOI: 10.3978/j.issn.2078-6891.2013.035] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
252 Lecomte T, Caulet M. Chimiothérapie (néo)adjuvante du cancer colique. Colon Rectum 2013;7:143-149. [DOI: 10.1007/s11725-013-0468-4] [Reference Citation Analysis]
253 Rousseau B, Tournigand C. Adjuvant treatment of stage III colon cancer: where are we and will we ever move forward? Personalized Management of Colorectal Cancer 2013. [DOI: 10.2217/ebo.13.124] [Reference Citation Analysis]
254 André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, Paul J, Sobrero A, Taieb J, Shields AF, Ohtsu A, Grothey A, Sargent DJ; for the IDEA Steering Committee. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep 2013;9:261-9. [PMID: 24032000 DOI: 10.1007/s11888-013-0181-6] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 9.1] [Reference Citation Analysis]
255 Tomao F, Papa A, Rossi L, Caruso D, Panici PB, Venezia M, Tomao S. Current status of bevacizumab in advanced ovarian cancer. Onco Targets Ther 2013;6:889-99. [PMID: 23901283 DOI: 10.2147/OTT.S46301] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
256 Zhou S, Yang Y, Yang Y, Tao H, Li D, Zhang J, Jiang G, Fang J. Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model. PLoS One 2013;8:e68589. [PMID: 23874680 DOI: 10.1371/journal.pone.0068589] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
257 Quante M, Varga J, Wang TC, Greten FR. The gastrointestinal tumor microenvironment. Gastroenterology 2013;145:63-78. [PMID: 23583733 DOI: 10.1053/j.gastro.2013.03.052] [Cited by in Crossref: 99] [Cited by in F6Publishing: 108] [Article Influence: 11.0] [Reference Citation Analysis]
258 Jitawatanarat P, Wee W. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol 2013;4:231-8. [PMID: 23730520 DOI: 10.3978/j.issn.2078-6891.2013.008] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
259 Dumont SN, Chibaudel B, Bengrine-lefèvre L, André T, de Gramont A. Adjuvant therapy in patients with stage II and III colon cancer under 70 years of age. Colorectal Cancer 2013;2:205-217. [DOI: 10.2217/crc.13.21] [Reference Citation Analysis]
260 Stein A, Schmoll HJ. Systemic treatment of liver metastases from colorectal cancer. Ther Adv Med Oncol. 2013;5:193-203. [PMID: 23634197 DOI: 10.1177/1758834012473347] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
261 Venook AP, Saltz LB. Biologic Agents in the Treatment of Colorectal Cancer: The Last Decade; the Lost Decade? American Society of Clinical Oncology Educational Book 2013. [DOI: 10.14694/edbook_am.2013.33.e121] [Reference Citation Analysis]
262 Dellas K, Höhler T, Reese T, Würschmidt F, Engel E, Rödel C, Wagner W, Richter M, Arnold D, Dunst J. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol 2013;8:90. [PMID: 23587311 DOI: 10.1186/1748-717X-8-90] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]